Joseph Ragaz

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. ncbi Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial
    Joseph Ragaz
    McGill University Health Center, Royal Victoria Hospital, 687 Pine Ave, Montreal, PQ, Canada H3A 1A1
    J Natl Cancer Inst 97:116-26. 2005
  2. ncbi The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Colum
    Pauline T Truong
    Department of Radiation Oncology, British Columbia Cancer Agency Vancouver Island Centre, British Columbia Cancer Agency, University of British Columbia, Victoria, BC, Canada
    Int J Radiat Oncol Biol Phys 68:59-65. 2007
  3. ncbi Increased use of adjuvant regional radiotherapy for node-positive breast cancer in British Columbia
    Boon Chua
    Radiation Therapy and Systemic Therapy Programs, British Columbia Cancer Agency, Vancouver Island Center, Victoria, British Columbia, Canada
    Breast J 10:38-44. 2004
  4. ncbi Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index
    Grace M Callagy
    Cancer Genomics Program, Department of Oncology, Hutchison Medical Research Council Research Centre, University of Cambridge, United Kingdom
    Clin Cancer Res 12:2468-75. 2006
  5. ncbi Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
  6. ncbi Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model
    Brian J Long
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Health Sciences Facility, Baltimore, MD 21201, USA
    J Natl Cancer Inst 96:456-65. 2004
  7. ncbi Dose density by any other name
    William Hryniuk
    J Clin Oncol 22:750-1; author reply 751-3. 2004
  8. ncbi Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin
    Torsten O Nielsen
    British Columbia Research Institute for Children's and Women's Health, Department of Pediatrics, Laboratory for Oncogenomic Research, University of British Columbia, Vancouver British Columbia, Canada
    Cancer Res 64:286-91. 2004
  9. ncbi EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
    Luke Hughes-Davies
    Cancer Research UK Wellcome Trust Institute and Department of Pathology, Tennis Court Road, Cambridge CB2 1QR, United Kingdom
    Cell 115:523-35. 2003
  10. ncbi Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer
    Cicely Bryce
    J Clin Oncol 21:4465; author reply 4465-6. 2003

Collaborators

Detail Information

Publications11

  1. ncbi Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial
    Joseph Ragaz
    McGill University Health Center, Royal Victoria Hospital, 687 Pine Ave, Montreal, PQ, Canada H3A 1A1
    J Natl Cancer Inst 97:116-26. 2005
    ..We report the analysis of data from the 20-year follow-up...
  2. ncbi The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Colum
    Pauline T Truong
    Department of Radiation Oncology, British Columbia Cancer Agency Vancouver Island Centre, British Columbia Cancer Agency, University of British Columbia, Victoria, BC, Canada
    Int J Radiat Oncol Biol Phys 68:59-65. 2007
    ....
  3. ncbi Increased use of adjuvant regional radiotherapy for node-positive breast cancer in British Columbia
    Boon Chua
    Radiation Therapy and Systemic Therapy Programs, British Columbia Cancer Agency, Vancouver Island Center, Victoria, British Columbia, Canada
    Breast J 10:38-44. 2004
    ..001 for both). Publication of randomized trials and a coordinated guideline implementation process in British Columbia was associated with a significant increase in the use of regional RT in women with one to three positive nodes...
  4. ncbi Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index
    Grace M Callagy
    Cancer Genomics Program, Department of Oncology, Hutchison Medical Research Council Research Centre, University of Cambridge, United Kingdom
    Clin Cancer Res 12:2468-75. 2006
    ..We validated the results in an independent series. Experimental Design and..
  5. ncbi Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
    ..These studies show that many basal-like tumors express HER1, which suggests candidate drugs for evaluation in these patients...
  6. ncbi Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model
    Brian J Long
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Health Sciences Facility, Baltimore, MD 21201, USA
    J Natl Cancer Inst 96:456-65. 2004
    ..However, further studies are needed to determine the most effective second-line therapy for tumors that progress on letrozole...
  7. ncbi Dose density by any other name
    William Hryniuk
    J Clin Oncol 22:750-1; author reply 751-3. 2004
  8. ncbi Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin
    Torsten O Nielsen
    British Columbia Research Institute for Children's and Women's Health, Department of Pediatrics, Laboratory for Oncogenomic Research, University of British Columbia, Vancouver British Columbia, Canada
    Cancer Res 64:286-91. 2004
    ..Thus, our study raises the possibility that 17AAG could prove to be an effective therapeutic agent for a large number of breast cancer patients by inhibiting the IGF-IR and ultimately uPA...
  9. ncbi EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
    Luke Hughes-Davies
    Cancer Research UK Wellcome Trust Institute and Department of Pathology, Tennis Court Road, Cambridge CB2 1QR, United Kingdom
    Cell 115:523-35. 2003
    ..The remarkable clinical overlap between sporadic EMSY amplification and familial BRCA2 deletion implicates a BRCA2 pathway in sporadic breast and ovarian cancer...
  10. ncbi Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer
    Cicely Bryce
    J Clin Oncol 21:4465; author reply 4465-6. 2003
  11. ncbi Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer
    Ivo A Olivotto
    Breast Cancer Outcomes Unit, Victoria, British Columbia, Canada
    J Clin Oncol 21:851-4. 2003
    ....